ChemicalBook > Product Catalog >Biochemical Engineering >Inhibitors >Cell Cycle >Aurora Kinase Inhibitors >ZM 447439

ZM 447439

ZM 447439 Suppliers list
Company Name: ATK CHEMICAL COMPANY LIMITED
Tel: +undefined-21-51877795
Email: ivan@atkchemical.com
Products Intro: Product Name:ZM 447439
CAS:331771-20-1
Purity:98% Package:10MG;50MG;100MG,1G,5G,10G.100G
Company Name: Hubei xin bonus chemical co. LTD
Tel: 86-13657291602
Email: linda@hubeijusheng.com
Products Intro: Product Name:ZM 447439
CAS:331771-20-1
Company Name: Alchem Pharmtech,Inc.
Tel: 8485655694
Email: sales@alchempharmtech.com
Products Intro: Product Name:N-[4-[[6-Methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]benzamide
CAS:331771-20-1
Purity:97+% Package:1g;10g;100g;;1kg Remarks:Z-24190
Company Name: CONIER CHEM AND PHARMA LIMITED
Tel: +8618523575427
Email: sales@conier.com
Products Intro: Product Name:zm-447439
CAS:331771-20-1
Purity:0.99 Package:1kg
Company Name: Dideu Industries Group Limited
Tel: +86-29-89586680 +86-15129568250
Email: 1026@dideu.com
Products Intro: Product Name:ZM 447439
CAS:331771-20-1
Purity:99.9% Package:25kgs/Drum;200kgs/Drum Remarks:FDA GMP CEP Approved Manufacturer
ZM 447439 Basic information
Description Features In vitro
Product Name:ZM 447439
Synonyms:N-[4-[[6-METHOXY-7-[3-(4-MORPHOLINYL)PROPOXY]-4-QUINAZOLINYL]AMINO]PHENYL]BENZAMIDE;ZM 447439;N-(4-((6-Methoxy-7-(3-Morpholinopropoxy)quinazolin-4-yl)aMino)phenyl)benzaMide;BenzaMide, N-[4-[[6-Methoxy-7-[3-(4-Morpholinyl)propoxy]-4-quinazolinyl]aMino]phenyl]-;ZM-447439;ZM447439;ZM 447439, >=98%;Aurora Kinase Inhibitor VI, ZM447439 - CAS 331771-20-1 - Calbiochem;CS-77
CAS:331771-20-1
MF:C29H31N5O4
MW:513.59
EINECS:
Product Categories:Inhibitor;Aromatics;Heterocycles;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals
Mol File:331771-20-1.mol
ZM 447439 Structure
ZM 447439 Chemical Properties
Melting point 117-120°C
Boiling point 639.7±55.0 °C(Predicted)
density 1.282±0.06 g/cm3(Predicted)
storage temp. Desiccate at RT
solubility Soluble in DMSO (up to 50 mg/ml) or in Ethanol (up to 25 mg/ml).
form White solid
pka13.01±0.70(Predicted)
color White
Stability:Stable for 1 year from date of purchase? as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months.
Safety Information
MSDS Information
ZM 447439 Usage And Synthesis
DescriptionZM 447439 is a selective and ATP-competitive inhibitor for Aurora A and Aurora B with IC50 of 110 nM and 130 nM, respectively. It is more than 8-fold selective for Aurora A/B than MEK1, Src, Lck and has little effect against CDK1/2/4, Plk1, Chk1, etc.
FeaturesAn Aurora selective ATP-competitive inhibitor.
In vitroIn vitro, ZM-447439 selectively inhibits recombinant human Aurora A and B with IC50 values of 110 and 130 nM, respectively, while other protein kinases of diverse structural types including the mitotic kinases CDK1 and PLK1 are inhibited with IC50 values >10 μM. Aurora kinase inhibitor, ZM-447439 time-and dose-dependently inhibits the growth of all three cell lines with IC50 values of 3 μM (BON), 0.9 μM (QGP-1) and 3 μM (MIP-101) after 72 hours of continuous exposure. In addition, ZM-447439 potently induces cell apoptosis by promoting DNA fragmentation and caspase 3 and 7 activation, and arrests GEP-NET cells in the G0 /G1and G2/M phase of the cell cycle. In mouse embryo, inhibition of Aurora kinase activity by ZM-447439 results in abnormalities during mitosis by regulating the phosphorylation of histone H3 serine 10 (H3S10Ph) from G2 to metaphase with different perturbations in each embryonic cycle. A recent study shows that ZM-447439 exhibits growth inhibitory and proapoptotic effect on cervical cancer SiHa cells, and enhances the chemosensitivity to cisplatin
DescriptionThe Aurora kinases have important roles in regulating mitosis and cytokinesis, with Aurora B involved in centromere function as part of the Chromosomal Passenger Complex, with survivin, INCENP, and borealin. ZM 447439 is a selective inhibitor of Aurora B kinase (IC50 = 50 nM), less potently inhibiting Aurora C and A (IC50 = 250 and 1,000 nM, respectively). It has no effect on several other kinases, including Cdk1, Cdk2, Cdk4, Plk1, CHK1, KDR2, and FAK (IC50 > 10 μM). ZM 447439 has been used to study the role of Aurora B in molecular events associated with mitosis and cytokinesis. Moreover, ZM 447439 selectively inhibits proliferating cells rather than non-dividing cells, suggesting its potential in cancer therapy.
Chemical PropertiesPale Yellow Solid
UsesIt is a potent and selective inhibitor of Aurora B kinase. Cells treated with ZM-447439 progress through interphase, enter mitosis and assemble bipolar spindles but chromosome alignment, segregation and cytokinesis all fail. It induces apoptosos in Hep2 cancer cells and in acute myeloid leukemia cell lines but its propensity to induce polyploidy does not inevitably result in apoptosis.
DefinitionChEBI: ZM447439 is a member of the class of quinazolines that is quinazoline which is substituted at positions 4, 6 and 7 by a (4-benzamidophenyl)nitrilo group, methoxy group and a 3-(morpholin-4-yl)propoxy group, respectively. It is an ATP-competitive inhibitor of Aurora A and Aurora B kinases with IC50 of 110 nM and 130 nM, respectively. It has a role as an Aurora kinase inhibitor, an antineoplastic agent and an apoptosis inducer. It is a member of benzamides, a member of quinazolines, an aromatic ether, a member of morpholines, a polyether, a secondary amino compound and a tertiary amino compound.
storageroom temperature (desiccate)
References1) Ditchfield et al (2003) Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores; J.Cell Biol. 161 267 2) Girdler et al. (2006) Validating Aurora B as an anti-cancer drug target; J. Cell Sci. 119 3664
ZM 447439 Preparation Products And Raw materials
Tag:ZM 447439(331771-20-1) Related Product Information
ZM223 TYRPHOSTIN AG 879 LFM-A13 AAL-993 Troglitazone ZM 323881 hydrochloride ZM 336372 ZM 39923 HCl ZM 241385 ZM 306416 Alisertib (MLN8237) Tozasertib BI 2536 Hesperadin MLN8054 Barasertib (AZD1152-HQPA) (3β)-3-[(4-Fluorobenzoyl)oxy]lup-20(29)-en-28-oic acid ZM 447439